Belize vs Kazakhstan: Average cost of multi drug-resistant tuberculosis treatment
Belize
3,017 constant 2022 US$
in 2024
Kazakhstan
3,398 constant 2022 US$
in 2023
Belize rank
15th
Kazakhstan rank
13th
Average cost of multi drug-resistant tuberculosis treatment over time
- Belize
- Kazakhstan
How they compare
Kazakhstan currently reports 3,398 constant 2022 US$ against 3,017 constant 2022 US$ in Belize, a difference of 381 constant 2022 US$.
That makes Kazakhstan's figure about 1.1 times Belize's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Kazakhstan ahead.
Belize ranks 15th and Kazakhstan ranks 13th of 92 countries.
Kazakhstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Belize | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,334 constant 2022 US$ | 3,848 constant 2022 US$ | 513.5 constant 2022 US$ | Kazakhstan |
| 2020s | 1,781 constant 2022 US$ | 2,932 constant 2022 US$ | 1,151 constant 2022 US$ | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Belize or Kazakhstan?
- Kazakhstan, at 3,398 constant 2022 US$ against 3,017 constant 2022 US$ in Belize as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Belize and Kazakhstan?
- 381 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Belize and Kazakhstan?
- 6 years are reported by both, from 2017 to 2023.
- How do Belize and Kazakhstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Belize ranks 15th and Kazakhstan ranks 13th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.